Dividend Power Score
A single, comprehensive score designed to measure the true strength of a company’s dividend.
This score combines three essential pillars of dividend quality:
Consistency – Measures how reliable the dividend has been over time, focusing on payment history, stability, and the absence of cuts or suspensions.
Payability – Assesses the company’s financial ability to sustain its dividend, taking into account cash flow, earnings coverage, balance sheet strength, and overall financial health.
Growth – Evaluates the long-term growth of both the dividend and the company’s share price, highlighting businesses that consistently increase payouts while creating shareholder value.
Higher scores identify companies that have historically delivered dependable income alongside sustained dividend growth and long-term capital appreciation.
Company Overview
TC Biopharm (Holdings) plc is a clinical-stage biotechnology company focused on the development of novel immunotherapies derived from gamma-delta (γδ) T cells. The company operates within the biopharmaceutical and biotechnology industries, specifically targeting oncology and hematological malignancies. Its core strategy centers on harnessing the innate immune properties of γδ T cells to develop allogeneic, off-the-shelf cell therapies designed to treat cancer patients with limited existing options.
The company’s primary value proposition lies in its proprietary γδ T-cell platform, which aims to deliver scalable, cryopreserved cell therapies with reduced risk of graft-versus-host disease compared to conventional alpha-beta T-cell approaches. TC Biopharm was founded in 2013 in the United Kingdom as a spin-out from academic research and has since evolved into a publicly traded company listed on Nasdaq through its American Depositary Shares under the ticker TCBPY, advancing multiple clinical-stage programs.
Business Operations
TC Biopharm’s operations are centered on research and development rather than commercial sales, as the company does not currently generate product revenue. Its principal business activities involve discovery, preclinical development, clinical trials, and regulatory engagement for its γδ T-cell therapies. The company’s lead therapeutic candidates are derived from its proprietary expansion and cryopreservation processes, which enable the production of allogeneic cell therapy products.
The company operates primarily through its wholly owned subsidiary TC BioPharm Limited, which conducts laboratory research, manufacturing development, and clinical trial coordination. TC Biopharm’s operations are predominantly based in the United Kingdom, with clinical activities extending internationally through hospital and research collaborations supporting its oncology trials.
Strategic Position & Investments
Strategically, TC Biopharm is focused on advancing its pipeline of γδ T-cell therapies through early- and mid-stage clinical development, with an emphasis on hematologic cancers such as acute myeloid leukemia and other blood-related malignancies. Growth initiatives are centered on progressing clinical trials, optimizing manufacturing scalability, and strengthening its intellectual property portfolio around γδ T-cell expansion and application.
The company has made targeted investments in proprietary manufacturing technologies rather than pursuing large-scale acquisitions, reflecting its capital-constrained, research-focused model. TC Biopharm does not report ownership of a broad investment portfolio or diversified subsidiaries; instead, its strategic assets consist primarily of internally developed technologies, clinical data, and regulatory designations supporting its lead candidates.
Geographic Footprint
TC Biopharm is headquartered in Scotland, United Kingdom, where it maintains its primary research and development facilities. The company’s operational footprint is concentrated in the UK, which serves as the hub for its scientific, manufacturing, and corporate functions.
Internationally, TC Biopharm has a limited but expanding presence through clinical trial activities and regulatory engagement in North America and parts of Europe. Its Nasdaq listing provides access to U.S. capital markets, supporting its global investor base and enabling participation in international clinical and regulatory pathways.
Leadership & Governance
TC Biopharm is led by an executive team with experience in biotechnology, drug development, and corporate governance, reflecting the company’s focus on advancing early-stage clinical assets while maintaining public company compliance. The leadership emphasizes disciplined capital allocation, scientific rigor, and strategic partnerships to advance its immunotherapy platform.
Key executives include:
- Angela Scott – Chief Executive Officer
- Cathal Fanning – Chief Financial Officer
- Garry Smith – Chief Operating Officer
- Professor Robert Hawkins – Chief Scientific Officer
The leadership team’s strategic vision centers on establishing γδ T-cell therapy as a differentiated modality in cancer treatment, with a long-term objective of achieving clinical validation and eventual commercialization through independent development or strategic collaborations.